
Alzheimers Disease Diagnostic Market Size, Share, and Analysis, By Type (Early Onset Alzheimers, Late Onset Alzheimers, Familial Alzheimers Disease, Others), By Diagnostic Test (PET, SPECT, Blood based ELISA Test, CSF Assays, Others), By End User (Clinic,
Description
Alzheimers Disease Diagnostic Market Size, Share, and Analysis, By Type (Early Onset Alzheimers, Late Onset Alzheimers, Familial Alzheimers Disease, Others), By Diagnostic Test (PET, SPECT, Blood based ELISA Test, CSF Assays, Others), By End User (Clinic, Hospital, Diagnostic Center, Others) and Regional Forecasts, 2022-2032
Alzheimers Disease Diagnostic Market Size, Share, and Analysis, By Type (Early Onset Alzheimers, Late Onset Alzheimers, Familial Alzheimers Disease, Others), By Diagnostic Test (PET, SPECT, Blood based ELISA Test, CSF Assays, Others), By End User (Clinic, Hospital, Diagnostic Center, Others) and Regional Forecasts, 2022-2032
PRODUCT OVERVIEW
Alzheimers Disease Diagnostic Market size was USD 3.3 billion in 2021 and projected to grow from USD 4.0 billion in 2023 to USD 9.6 billion by 2032, exhibiting a CAGR of 10.2% during the forecast period.
Alzheimer's is a brain illness that gradually impairs thinking and memory abilities as well as the capacity to do even the most basic tasks. Growing age is the key known risk aspect for the said disease. Alzheimer's is diagnosed by doctors using a patient's mental status tests, medical history, neurological and physical examinations, diagnostic tests, and brain imaging. The illness is the most typical cause of dementia in elderly people.
MARKET HIGHLIGHTS
Alzheimers Disease Diagnostic Market is expected to reach USD 9.6 billion, growing at a CAGR of 10.2% during the forecast period owing to increasing number of chronic illnesses like dementia, rising pipeline medicine development, and funding in biomarkers for development of drugs. The expanding treatment choices and better diagnostic procedures for the early finding of chronic illnesses is another major driver for the growth of the Alzheimers Disease Diagnostic Market.
Alzheimers Disease Diagnostic Market Segments:
- Type
- Early Onset Alzheimers
- Late Onset Alzheimers
- Familial Alzheimers Disease
- Others
- Diagnostic Test
- PET
- SPECT
- Blood based ELISA Test
- CSF Assays
- Others
- End User
- Clinic
- Hospital
- Diagnostic Center
- Others
Growth Drivers
Global Rise in Chronic Illnesses and Improvements in Diagnostics and Detection of Alzheimers is Expected to Boost the Market Growth
Number of Government Initiatives and Funding by Institutions for R&D are Expected to Boost the Market Growth
Restraint
Lengthy Clinical Trials and Huge Investments with Risk of Failure May Restrain the Market Growth
Key Players
- Johnson & Johnson
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Merck & Co.
- GE Healthcare
- AbbVie
- Eli Lilly and Company
- Daiichi Sankyo
- Sysmex
- Quanterix
- Alector LLC
- Corium Inc
- TauRx Therapeutics
- Cognition Therapeutics Inc
- Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
- Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 3-month post-sales analyst support.
Table of Contents
374 Pages
- 1. Executive Summary
- 1.1.Regional Market Share
- 1.2. Business Trends
- 1.3. Alzheimers Disease Diagnostic Market: COVID-19 Outbreak
- 1.4.Regional Trends
- 1.5. Segmentation Snapshot
- 2. Research Methodology
- 2.1. Research Objective
- 2.2.Research Approach
- 2.3.Data Sourcing and Methodology
- 2.4. Primary Research
- 2.5. Secondary Research
- 2.5.1.Paid Sources
- 2.5.2. Public Sources
- 2.6.Market Size Estimation and Data Triangulation
- 3. Market Characteristics
- 3.1. Market Definition
- 3.2.Alzheimers Disease Diagnostic Market: COVID-19 Impact
- 3.3.Key Segmentations
- 3.4. Key Developments
- 3.5. Allied Industry Data
- 4. Alzheimers Disease Diagnostic Market – Industry Insights
- 4.1.Industry Segmentation
- 4.2. COVID-19 overview on world economy
- 4.3. Industry ecosystem Channel analysis
- 4.4. Innovation & Sustainability
- 5. Macroeconomic Indicators
- 6. Recent Developments
- 7.Market Dynamics
- 7.1. Introduction
- 7.2.Growth Drivers
- 7.3.Market Opportunities
- 7.4. Market Restraints
- 7.5.Market Trends
- 8. Market Analysis
- 8.1. Porters Five Forces
- 8.2. PEST Analysis
- 8.2.1. Political
- 8.2.2.Economic
- 8.2.3.Social
- 8.2.4.Technological
- 9. Alzheimers Disease Diagnostic Market
- 9.1. Overview
- 9.2.Historical Analysis (2016-2021)
- 9.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
- 10. Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
- 10.1.Overview
- 10.2. Key Findings
- 10.3. Market Segmentation
- 10.3.1. By Type
- 10.3.1.1.Early Onset Alzheimers
- 10.3.1.1.1.By Value (USD Million) 2022-2032F
- 10.3.1.1.2. Market Share (%) 2022-2032F
- 10.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
- 10.3.1.2. Late Onset Alzheimers
- 10.3.1.2.1. By Value (USD Million) 2022-2032F
- 10.3.1.2.2.Market Share (%) 2022-2032F
- 10.3.1.2.3.Y-o-Y Growth (%) 2022-2032F
- 10.3.1.3. Familial Alzheimers Disease
- 10.3.1.3.1. By Value (USD Million) 2022-2032F
- 10.3.1.3.2.Market Share (%) 2022-2032F
- 10.3.1.3.3.Y-o-Y Growth (%) 2022-2032F
- 10.3.1.4. Others
- 10.3.1.4.1.By Value (USD Million) 2022-2032F
- 10.3.1.4.2. Market Share (%) 2022-2032F
- 10.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
- 10.3.2.By Diagnostic Test
- 10.3.2.1. PET
- 10.3.2.1.1. By Value (USD Million) 2022-2032F
- 10.3.2.1.2.Market Share (%) 2022-2032F
- 10.3.2.1.3.Y-o-Y Growth (%) 2022-2032F
- 10.3.2.2.SPECT
- 10.3.2.2.1.By Value (USD Million) 2022-2032F
- 10.3.2.2.2. Market Share (%) 2022-2032F
- 10.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
- 10.3.2.3.Blood based ELISA Test
- 10.3.2.3.1.By Value (USD Million) 2022-2032F
- 10.3.2.3.2. Market Share (%) 2022-2032F
- 10.3.2.3.3.Y-o-Y Growth (%) 2022-2032F
- 10.3.2.4.CSF Assays
- 10.3.2.4.1. By Value (USD Million) 2022-2032F
- 10.3.2.4.2.Market Share (%) 2022-2032F
- 10.3.2.4.3.Y-o-Y Growth (%) 2022-2032F
- 10.3.2.5.Others
- 10.3.2.5.1.By Value (USD Million) 2022-2032F
- 10.3.2.5.2.Market Share (%) 2022-2032F
- 10.3.2.5.3.Y-o-Y Growth (%) 2022-2032F
- 10.3.3.By End User
- 10.3.3.1. Clinic
- 10.3.3.1.1. By Value (USD Million) 2022-2032F
- 10.3.3.1.2.Market Share (%) 2022-2032F
- 10.3.3.1.3.Y-o-Y Growth (%) 2022-2032F
- 10.3.3.2.Hospital
- 10.3.3.2.1.By Value (USD Million) 2022-2032F
- 10.3.3.2.2. Market Share (%) 2022-2032F
- 10.3.3.2.3.Y-o-Y Growth (%) 2022-2032F
- 10.3.3.3.Diagnostic Center
- 10.3.3.3.1.By Value (USD Million) 2022-2032F
- 10.3.3.3.2.Market Share (%) 2022-2032F
- 10.3.3.3.3.Y-o-Y Growth (%) 2022-2032F
- 10.3.3.4.Others
- 10.3.3.4.1. By Value (USD Million) 2022-2032F
- 10.3.3.4.2.Market Share (%) 2022-2032F
- 10.3.3.4.3.Y-o-Y Growth (%) 2022-2032F
- 11.North America Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
- 11.1.Overview
- 11.2. Key Findings
- 11.3. Market Segmentation
- 11.3.1.By Type
- 11.3.2. By Diagnostic Test
- 11.3.3. By End User
- 11.4.Country
- 11.4.1. United States
- 11.4.2.Canada
- 12. Europe Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
- 12.1. Overview
- 12.2. Key Findings
- 12.3. Market Segmentation
- 12.3.1. By Type
- 12.3.2.By Diagnostic Test
- 12.3.3.By End User
- 12.4. Country
- 12.4.1.Germany
- 12.4.2. United Kingdom
- 12.4.3. France
- 12.4.4. Italy
- 12.4.5. Spain
- 12.4.6. Russia
- 12.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
- 13. Asia Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
- 13.1. Overview
- 13.2. Key Findings
- 13.3. Market Segmentation
- 13.3.1. By Type
- 13.3.2.By Diagnostic Test
- 13.3.3.By End User
- 13.4. Country
- 13.4.1.India
- 13.4.2. China
- 13.4.3. South Korea
- 13.4.4. Japan
- 13.4.5. Rest of APAC
- 14. Middle East and Africa Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
- 14.1.Overview
- 14.2. Key Findings
- 14.3. Market Segmentation
- 14.3.1. By Type
- 14.3.2.By Diagnostic Test
- 14.3.3.By End User
- 14.4. Country
- 14.4.1.Israel
- 14.4.2. GCC
- 14.4.3. North Africa
- 14.4.4. South Africa
- 14.4.5. Rest of Middle East and Africa
- 15. Latin America Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
- 15.1.Overview
- 15.2. Key Findings
- 15.3. Market Segmentation
- 15.3.1. By Type
- 15.3.2.By Diagnostic Test
- 15.3.3.By End User
- 15.4. Country
- 15.4.1.Mexico
- 15.4.2. Brazil
- 15.4.3. Rest of Latin America
- 16. Competitive Landscape
- 16.1. Company market share, 2021
- 16.2. Key player overview
- 16.3. Key stakeholders
- 17. Company Profiles
- 17.1.Johnson & Johnson
- 17.1.1.Company Overview
- 17.1.2. Financial Overview
- 17.1.3. Key Product; Analysis
- 17.1.4.Company Assessment
- 17.1.4.1.Product Portfolio
- 17.1.4.2. Key Clients
- 17.1.4.3. Market Share
- 17.1.4.4. Recent News & Development (Last 3 Yrs.)
- 17.1.4.5. Executive Team
- 17.2. Novartis AG
- 17.3. F. Hoffmann-La Roche Ltd
- 17.4. Pfizer Inc.
- 17.5. Merck & Co.
- 17.6. GE Healthcare
- 17.7. AbbVie
- 17.8. Eli Lilly and Company
- 17.9. Daiichi Sankyo
- 17.10. Sysmex
- 17.11.Quanterix
- 17.12. Alector LLC
- 17.13. Corium Inc
- 17.14. TauRx Therapeutics
- 17.15. Cognition Therapeutics Inc
- 17.16. Other Prominent Players
- 18. Appendix
- 19. Consultant Recommendation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.